Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
N!%LOCK|!tLOCK|fRJD%q

Merck: Cidara Acquisition Builds on Respiratory Disease Focus at a Fair Price

On Nov. 14, Merck announced an agreement to acquire Cidara and its phase 3 influenza prevention antiviral, CD388, for $9.2 billion.

Sponsor Center